Genetic Vaccines and Therapy最新文献_第8页

Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. 呼吸道合胞病毒感染Fischer 344大鼠可通过短干扰RNA抑制RSV-NS1基因。

Genetic Vaccines and Therapy Pub Date : 2007-02-01 DOI: 10.1186/1479-0556-5-4

Xiaoyuan Kong, Weidong Zhang, Richard F Lockey, Alexander Auais, Giovanni Piedimonte, Shyam S Mohapatra

{"title":"Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene.","authors":"Xiaoyuan Kong, Weidong Zhang, Richard F Lockey, Alexander Auais, Giovanni Piedimonte, Shyam S Mohapatra","doi":"10.1186/1479-0556-5-4","DOIUrl":"https://doi.org/10.1186/1479-0556-5-4","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) causes severe bronchiolitis and is a risk factor for asthma. Since there is no commercially available vaccine against RSV, a short interfering RNA against the RSV-NS1gene (siNS1) was developed and its potential for decreasing RSV infection and infection-associated inflammation in rats was tested.Methods: Plasmids encoding siNS1 or an unrelated siRNA were complexed with a chitosan nanoparticle delivery agent and administered intranasally. Control animals received a plasmid for a non-specific siRNA. After expression of the plasmid in lung cells for 24 hours, the rats were intranasally infected with RSV.Results: Prophylaxis with siNS1 significantly reduced lung RSV titers and airway hyperreactivity to methacholine challenge compared to the control group. Lung sections from siNS1-treated rats showed a sizable reduction in goblet cell hyperplasia and in lung infiltration by inflammatory cells, both characteristics of asthma. Also, bronchoalveolar lavage samples from siNS1-treated animals had fewer eosinophils. Treatment of rats with siNS1 prior to RSV exposure was effective in reducing virus titers in the lung and in preventing the inflammation and airway hyperresponsiveness associated with the infection that has been linked to development of asthma.Conclusion: The use of siNS1 prophylaxis may be an effective method for preventing RSV bronchiolitis and potentially reducing the later development of asthma associated with severe respiratory infections.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"5 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2007-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-5-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26526602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 55

Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120. 基于乳酸乳球菌的表达HIV gp120 DNA疫苗的免疫学分析

Genetic Vaccines and Therapy Pub Date : 2007-01-29 DOI: 10.1186/1479-0556-5-3

Gregers J Gram, Anders Fomsgaard, Mette Thorn, Søren M Madsen, Jacob Glenting

{"title":"Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120.","authors":"Gregers J Gram, Anders Fomsgaard, Mette Thorn, Søren M Madsen, Jacob Glenting","doi":"10.1186/1479-0556-5-3","DOIUrl":"https://doi.org/10.1186/1479-0556-5-3","url":null,"abstract":"For reasons of efficiency Escherichia coli is used today as the microbial factory for production of plasmid DNA vaccines. To avoid hazardous antibiotic resistance genes and endotoxins from plasmid systems used nowadays, we have developed a system based on the food-grade Lactococcus lactis and a plasmid without antibiotic resistance genes. We compared the L. lactis system to a traditional one in E. coli using identical vaccine constructs encoding the gp120 of HIV-1. Transfection studies showed comparable gp120 expression levels using both vector systems. Intramuscular immunization of mice with L. lactis vectors developed comparable gp120 antibody titers as mice receiving E. coli vectors. In contrast, the induction of the cytolytic response was lower using the L. lactis vector. Inclusion of CpG motifs in the plasmids increased T-cell activation more when the E. coli rather than the L. lactis vector was used. This could be due to the different DNA content of the vector backbones. Interestingly, stimulation of splenocytes showed higher adjuvant effect of the L. lactis plasmid. The study suggests the developed L. lactis plasmid system as new alternative DNA vaccine system with improved safety features. The different immune inducing properties using similar gene expression units, but different vector backbones and production hosts give information of the adjuvant role of the silent plasmid backbone. The results also show that correlation between the in vitro adjuvanticity of plasmid DNA and its capacity to induce cellular and humoral immune responses in mice is not straight forward.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"5 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2007-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-5-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26520433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs. 不同DNA疫苗递送系统对小鼠和豚鼠结核病诱导保护作用的比较。

Genetic Vaccines and Therapy Pub Date : 2007-01-24 DOI: 10.1186/1479-0556-5-2

Lúcia de Paula, Célio L Silva, Daniela Carlos, Camila Matias-Peres, Carlos A Sorgi, Edson G Soares, Patrícia R M Souza, Carlos R Z Bladés, Fábio C S Galleti, Vânia L D Bonato, Eduardo D C Gonçalves, Erika V G Silva, Lúcia H Faccioli

{"title":"Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs.","authors":"Lúcia de Paula, Célio L Silva, Daniela Carlos, Camila Matias-Peres, Carlos A Sorgi, Edson G Soares, Patrícia R M Souza, Carlos R Z Bladés, Fábio C S Galleti, Vânia L D Bonato, Eduardo D C Gonçalves, Erika V G Silva, Lúcia H Faccioli","doi":"10.1186/1479-0556-5-2","DOIUrl":"https://doi.org/10.1186/1479-0556-5-2","url":null,"abstract":"The great challenges for researchers working in the field of vaccinology are optimizing DNA vaccines for use in humans or large animals and creating effective single-dose vaccines using appropriated controlled delivery systems. Plasmid DNA encoding the heat-shock protein 65 (hsp65) (DNAhsp65) has been shown to induce protective and therapeutic immune responses in a murine model of tuberculosis (TB). Despite the success of naked DNAhsp65-based vaccine to protect mice against TB, it requires multiple doses of high amounts of DNA for effective immunization. In order to optimize this DNA vaccine and simplify the vaccination schedule, we coencapsulated DNAhsp65 and the adjuvant trehalose dimycolate (TDM) into biodegradable poly (DL-lactide-co-glycolide) (PLGA) microspheres for a single dose administration. Moreover, a single-shot prime-boost vaccine formulation based on a mixture of two different PLGA microspheres, presenting faster and slower release of, respectively, DNAhsp65 and the recombinant hsp65 protein was also developed. These formulations were tested in mice as well as in guinea pigs by comparison with the efficacy and toxicity induced by the naked DNA preparation or BCG. The single-shot prime-boost formulation clearly presented good efficacy and diminished lung pathology in both mice and guinea pigs.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"5 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2007-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-5-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26511479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. 慢病毒介导的IIIA型粘多糖病基因校正。

Genetic Vaccines and Therapy Pub Date : 2007-01-16 DOI: 10.1186/1479-0556-5-1

Donald S Anson, Chantelle McIntyre, Belinda Thomas, Rachel Koldej, Enzo Ranieri, Ainslie Roberts, Peter R Clements, Kylie Dunning, Sharon Byers

{"title":"Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.","authors":"Donald S Anson, Chantelle McIntyre, Belinda Thomas, Rachel Koldej, Enzo Ranieri, Ainslie Roberts, Peter R Clements, Kylie Dunning, Sharon Byers","doi":"10.1186/1479-0556-5-1","DOIUrl":"https://doi.org/10.1186/1479-0556-5-1","url":null,"abstract":"Background: Mucopolysaccharidosis type IIIA (MPS IIIA) is the most common of the mucopolysaccharidoses. The disease is caused by a deficiency of the lysosomal enzyme sulphamidase and results in the storage of the glycosaminoglycan (GAG), heparan sulphate. MPS IIIA is characterised by widespread storage and urinary excretion of heparan sulphate, and a progressive and eventually profound neurological course. Gene therapy is one of the few avenues of treatment that hold promise of a sustainable treatment for this disorder.Methods: The murine sulphamidase gene cDNA was cloned into a lentiviral vector and high-titre virus produced. Human MPS IIIA fibroblast cultures were transduced with the sulphamidase vector and analysed using molecular, enzymatic and metabolic assays. High-titre virus was intravenously injected into six 5-week old MPS IIIA mice. Three of these mice were pre-treated with hyperosmotic mannitol. The weight of animals was monitored and GAG content in urine samples was analysed by polyacrylamide gel electrophoresis.Results: Transduction of cultured MPS IIIA fibroblasts with the sulphamidase gene corrected both the enzymatic and metabolic defects. Sulphamidase secreted by gene-corrected cells was able to cross correct untransduced MPS IIIA cells. Urinary GAG was found to be greatly reduced in samples from mice receiving the vector compared to untreated MPS IIIA controls. In addition, the weight of treated mice became progressively normalised over the 6-months post-treatment.Conclusion: Lentiviral vectors appear promising vehicles for the development of gene therapy for MPS IIIA.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"5 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2007-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-5-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26492522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Characterization of the ribonuclease activity on the skin surface. 皮肤表面核糖核酸酶活性的表征。

Genetic Vaccines and Therapy Pub Date : 2006-05-29 DOI: 10.1186/1479-0556-4-4

Jochen Probst, Sonja Brechtel, Birgit Scheel, Ingmar Hoerr, Günther Jung, Hans-Georg Rammensee, Steve Pascolo

引用次数: 80

Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. 利用反义寡核苷酸诱导mdx小鼠的反向纤维。

Genetic Vaccines and Therapy Pub Date : 2006-05-24 DOI: 10.1186/1479-0556-4-3

Abbie M Fall, Russell Johnsen, Kaite Honeyman, Pat Iversen, Susan Fletcher, Stephen D Wilton

{"title":"Induction of revertant fibres in the mdx mouse using antisense oligonucleotides.","authors":"Abbie M Fall, Russell Johnsen, Kaite Honeyman, Pat Iversen, Susan Fletcher, Stephen D Wilton","doi":"10.1186/1479-0556-4-3","DOIUrl":"https://doi.org/10.1186/1479-0556-4-3","url":null,"abstract":"Background: Duchenne muscular dystrophy is a fatal genetic disorder caused by dystrophin gene mutations that result in premature termination of translation and the absence of functional protein. Despite the primary dystrophin gene lesion, immunostaining studies have shown that at least 50% of DMD patients, mdx mice and a canine model of DMD have rare dystrophin-positive or 'revertant' fibres. Fine epitope mapping has shown that the majority of transcripts responsible for revertant fibres exclude multiple exons, one of which includes the dystrophin mutation.Methods: The mdx mouse model of muscular dystrophy has a nonsense mutation in exon 23 of the dystrophin gene. We have shown that antisense oligonucleotides (AOs) can induce the removal of this exon, resulting in an in-frame mRNA transcript encoding a shortened but functional dystrophin protein. To emulate one exonic combination associated with revertant fibres, we target multiple exons for removal by the application of a group of AOs combined as a \"cocktail\".Results: Exons 19-25 were consistently excluded from the dystrophin gene transcript using a cocktail of AOs. This corresponds to an alternatively processed gene transcript that has been sporadically detected in untreated dystrophic mouse muscle, and is presumed to give rise to a revertant dystrophin isoform. The transcript and the resultant correctly localised smaller protein were confirmed by RT-PCR, immunohistochemistry and western blot analysis.Conclusion: This work demonstrates the feasibility of AO cocktails to by-pass dystrophin mutation hotspots through multi-exon skipping. Multi-exon skipping could be important in expediting an exon skipping therapy to treat DMD, so that the same AO formulations may be applied to several different mutations within particular domains of the dystrophin gene.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"4 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2006-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-4-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26039216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 66

Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. 注射阳离子脂质配制的pDNA疫苗后，持续的狂犬病保护性中和抗体滴度。

Genetic Vaccines and Therapy Pub Date : 2006-02-15 DOI: 10.1186/1479-0556-4-2

Michal Margalith, Adrián Vilalta

引用次数: 29

Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery. 编码Hsp65基因的质粒DNA的组织分布依赖于通过肌肉注射给药的剂量。

Genetic Vaccines and Therapy Pub Date : 2006-01-30 DOI: 10.1186/1479-0556-4-1

A A M Coelho-Castelo, A P Trombone, R S Rosada, R R Santos, V L D Bonato, A Sartori, C L Silva

{"title":"Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery.","authors":"A A M Coelho-Castelo, A P Trombone, R S Rosada, R R Santos, V L D Bonato, A Sartori, C L Silva","doi":"10.1186/1479-0556-4-1","DOIUrl":"https://doi.org/10.1186/1479-0556-4-1","url":null,"abstract":"In order to assess a new strategy of DNA vaccine for a more complete understanding of its action in immune response, it is important to determine the in vivo biodistribution fate and antigen expression. In previous studies, our group focused on the prophylactic and therapeutic use of a plasmid DNA encoding the Mycobacterium leprae 65-kDa heat shock protein (Hsp65) and achieved an efficient immune response induction as well as protection against virulent M. tuberculosis challenge. In the present study, we examined in vivo tissue distribution of naked DNA-Hsp65 vaccine, the Hsp65 message, genome integration and methylation status of plasmid DNA. The DNA-Hsp65 was detectable in several tissue types, indicating that DNA-Hsp65 disseminates widely throughout the body. The biodistribution was dose-dependent. In contrast, RT-PCR detected the Hsp65 message for at least 15 days in muscle or liver tissue from immunized mice. We also analyzed the methylation status and integration of the injected plasmid DNA into the host cellular genome. The bacterial methylation pattern persisted for at least 6 months, indicating that the plasmid DNA-Hsp65 does not replicate in mammalian tissue, and Southern blot analysis showed that plasmid DNA was not integrated. These results have important implications for the use of DNA-Hsp65 vaccine in a clinical setting and open new perspectives for DNA vaccines and new considerations about the inoculation site and delivery system.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"4 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2006-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-4-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25828039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

A trial of somatic gene targeting in vivo with an adenovirus vector. 用腺病毒载体在体内靶向体细胞基因的试验。

Genetic Vaccines and Therapy Pub Date : 2005-10-12 DOI: 10.1186/1479-0556-3-8

Asami Ino, Yasuhiro Naito, Hiroyuki Mizuguchi, Naofumi Handa, Takao Hayakawa, Ichizo Kobayashi

{"title":"A trial of somatic gene targeting in vivo with an adenovirus vector.","authors":"Asami Ino, Yasuhiro Naito, Hiroyuki Mizuguchi, Naofumi Handa, Takao Hayakawa, Ichizo Kobayashi","doi":"10.1186/1479-0556-3-8","DOIUrl":"https://doi.org/10.1186/1479-0556-3-8","url":null,"abstract":"Background: Gene targeting in vivo provides a potentially powerful method for gene analysis and gene therapy. In order to sensitively detect and accurately measure designed sequence changes, we have used a transgenic mouse system, MutaMouse, which has been developed for detection of mutation in vivo. It carries bacteriophage lambda genome with lacZ+ gene, whose change to lacZ-negative allele is detected after in vitro packaging into bacteriophage particles. We have also demonstrated that gene transfer with a replication-defective adenovirus vector can achieve efficient and accurate gene targeting in vitro.Methods: An 8 kb long DNA corresponding to the bacteriophage lambda transgene with one of two lacZ-negative single-base-pair-substitution mutant allele was inserted into a replication-defective adenovirus vector. This recombinant adenovirus was injected to the transgenic mice via tail-vein. Twenty-four hours later, genomic DNA was extracted from the liver tissue and the lambda::lacZ were recovered by in vitro packaging. The lacZ-negative phage was detected as a plaque former on agar with phenyl-beta-D-galactoside.Results: The mutant frequency of the lacZ-negative recombinant adenovirus injected mice was at the same level with the control mouse (approximately 1/10000). Our further restriction analysis did not detect any designed recombinant.Conclusion: The frequency of gene targeting in the mouse liver by these recombinant adenoviruses was shown to be less than 1/20000 in our assay. However, these results will aid the development of a sensitive, reliable and PCR-independent assay for gene targeting in vivo mediated by virus vectors and other means.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"3 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2005-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-3-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25642931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 43

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. 用于转移性黑色素瘤疫苗的肿瘤衍生扩增cRNA文库的生产和表征

Genetic Vaccines and Therapy Pub Date : 2005-08-22 DOI: 10.1186/1479-0556-3-6

Jean-Philippe Carralot, Benjamin Weide, Oliver Schoor, Jochen Probst, Birgit Scheel, Regina Teufel, Ingmar Hoerr, Claus Garbe, Hans-Georg Rammensee, Steve Pascolo

{"title":"Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.","authors":"Jean-Philippe Carralot, Benjamin Weide, Oliver Schoor, Jochen Probst, Birgit Scheel, Regina Teufel, Ingmar Hoerr, Claus Garbe, Hans-Georg Rammensee, Steve Pascolo","doi":"10.1186/1479-0556-3-6","DOIUrl":"https://doi.org/10.1186/1479-0556-3-6","url":null,"abstract":"Background: Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients with autologous amplified tumor mRNA. In order to provide the large quantities of mRNA needed for each patient, the Stratagene Creator SMART cDNA library construction method was modified and applied to produce libraries derived from the tumors of 15 patients. The quality of those mRNA library vaccines was evaluated through sequencing and microarray analysis.Results: Random analysis of bacterial clones of the library showed a rate of 95% of recombinant plasmids among which a minimum of 51% of the clones contained a full-Open Reading Frame. In addition, despite a biased amplification toward small abundant transcripts compared to large rare fragments, we could document a relatively conserved gene expression profile between the total RNA of the tumor of origin and the corresponding in vitro transcribed complementary RNA (cRNA). Finally, listing the 30 most abundant transcripts of patient MEL02's library, a large number of tumor associated antigens (TAAs) either patient specific or shared by several melanomas were found.Conclusion: Our results show that unlimited amounts of cRNA representing tumor's transcriptome could be obtained and that this cRNA was a reliable source of a large variety of tumor antigens.","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"3 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2005-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-3-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25261208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9